Research Paper Volume 15, Issue 14 pp 6757—6773
PARP10 is highly expressed and associated with inferior outcomes in acute myeloid leukemia
Figure 4. Survival analysis of AML patients who received intensive chemotherapy or intensive chemotherapy followed by allo-SCT, according to PARP10 expression. Overall survival rate (A) and event-free survival rate (B) of AML patients who received intensive chemotherapy versus intensive chemotherapy followed by allo-SCT in the PARP10 high group. Overall survival rate (C) and event-free survival rate (D) of AML patients who received intensive chemotherapy versus intensive chemotherapy followed by allo-SCT in the PARP10 low group.